The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Abstract
The success or failure of antimicrobial therapy in bacterial and fungal infections is predicted ideally by antimicrobial susceptibility testing (AST), in which microorganisms are divided into treatable and non-treatable categories on the basis of MIC breakpoints. In Europe, the categorization was traditionally a clinical one and it was made irrespective of whether or not the organism harboured resistance mechanisms. MIC breakpoints generally divide bacteria into three categories of susceptibility: susceptible, intermediate or indeterminate, or resistant. These terms can be defined as susceptible (S—where the antimicrobial activity is associated with a likelihood of therapeutic success), intermediate or indeterminate (I—where the antimicrobial activity is associated with an indeterminate or uncertain therapeutic effect) and resistant (R—where the antimicrobial activity is associated with a higher than expected likelihood of therapeutic failure). MIC breakpoints are used either directly, as in MIC determination and ‘breakpoint’ susceptibility testing methods in broth or agar, or indirectly when converted into inhibition zone diameters in disc diffusion techniques. The last decade has demonstrated that breakpoints need a new function: to detect the biological phenomenon of phenotypical resistance, and to monitor the development of antimicrobial resistance. The need for this new function has shown us firstly, that breakpoints designed to guide therapy do not necessarily distinguish between bacteria with and without resistance mechanisms, and do not necessarily allow their early and/or reproducible detection. Secondly, it has demonstrated that the lack of harmonized breakpoints among methods in different countries, or even within the same country, often obviates meaningful comparison of resistance rates, monitoring of development of resistance in international surveillance systems and investigation of the effects of intervention strategies. Breakpoints have evolved to try to satisfy both the need to guide therapy and the need to detect biological resistance, often resulting in compromises that satisfy neither. MIC breakpoints may be defined by national breakpoint committees and/or regulatory authorities, including medicines’ agencies, such as the European Medicines Evaluation Agency (EMEA) in Europe, and the Food and Drug Administration (FDA) in the USA. In Europe, there are several active national breakpoint committees, including CA-SFM1 in France, the DIN2 in Germany, the CRG3 in the Netherlands, the NWGA4 in Norway, the SRGA5 in Sweden and the BSAC Working Party on Antimicrobial Sensitivity Testing6 in the UK. Each committee is long established, has 8–15 members from the fields of clinical microbiology, infectious diseases, pharmacology and, in some cases, from other fields of medicine. Each committee has devised a process for defining breakpoints. Several also have described AST methodologies to go with their breakpoints, but with few exceptions these methodologies are limited to their respective country. The equivalent committee in the USA is the NCCLS7 with many adherents worldwide, including European countries. It seems little more than chance that the committees occasionally recommend the same breakpoints and use the same terminology and/or methods. For example, the quite remarkable differences in cefotaxime and ciprofloxacin breakpoints for Enterobacteriaceae are shown in Table 1. The difference in terminology is exemplified by the different signs used for separating the intermediate and resistant categories, CA-SFM and CRG using R > X mg/L, whereas the others, including the NCCLS, use R ≥ X mg/L. Although MIC determination methodologies are similar, all having the same origin, there are some differences in the recommended media. For disc diffusion methods the differences are even greater. European committees normally recommend a lighter inoculum than the confluent inoculum recommended by NCCLS, and there are differences in media, disc contents, incubation conditions and other technical details. The lack of harmonization of breakpoints, terminology and methods creates difficulties in the comparison of results of antimicrobial surveillance, and in communication between the medical profession, the pharmaceutical industry and the regulatory authorities. Antimicrobial chemotherapy is generally similar in different countries and it is not logical for the same organism to be regarded as susceptible in some countries whereas resistant in others. MIC breakpoints are defined against a background of data, including intended or approved indications, clinical response data, dosing schedules, pharmacokinetics and pharmacodynamics, and microbiological data in a variety of formats. The process of setting breakpoints never was, and probably never will be, exact or strictly scientific; it contains elements of philosophy, ‘fairness’ and compromise. One might be sceptical at the introduction of a ‘shift factor’ as part of
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
[Antibiogram Committee of the French Society for Microbiology. Official Statement 1999].
Soussy, C. (1999) · PubMed · Cited by 677
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests
MacGowan, A. P., & Wise, R. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.suppl_1.17 · Cited by 187
Breakpoints: current practice and future perspectives
Mouton, J. W. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00028-6 · Cited by 75
Antimicrobial susceptibility testing of Mycobacterium tuberculosis
Dorbniewski, F. (2002) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2002.00478.x · Cited by 12
Cited by
Wiegand, I., Hilpert, K., & Hancock, R. E. W. (2008) · Nature Protocols · doi:10.1038/nprot.2007.521 · Cited by 6,156
The global threat of antimicrobial resistance: science for intervention.
Roca, I., Akova, M., Baquero, F., Carlet, J., Cavaleri, M., Coenen, S., Cohen, J., Findlay, D., Gyssens, I., Heure, O. E., et al. (2015) · New Microbes and New Infections · doi:10.1016/j.nmni.2015.02.007 · Cited by 1,106
“At the international level, breakpoints are officially determined by two main institutions: the Clinical and Laboratory Standards Institute (CLSI) in the United States, which is a not-for-profit membership organization sponsored by the industry and the medical community; and the European Committee on Antimicrobial Sus…”
BackgroundSelf-citationWhat is a resistance gene? Ranking risk in resistomes
Martínez, J. L., Coque, T. M., & Baquero, F. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3399 · Cited by 1,001
Matuschek, E., Brown, D. F. J., & Kahlmeter, G. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12373 · Cited by 887
Self-citationAuthority, E. F. S., & European Centre for Disease Prevention and Control (2021) · EFSA Journal · doi:10.2903/j.efsa.2021.6490 · Cited by 874
Metadata
- Authors
- Kahlmeter, G.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-07-01
- Volume
- 52
- Issue
- 2
- Pages
- 145-148
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2147356875
- Cited by
- 397
- References
- 6
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.